The biomarker CD163 can predict mortality in blood samples from patients with acute on chronic liver failure, report scientists. Acute-on-chronic liver failure (ACLF) is a sudden deterioration of the liver function in a patient with liver cirrhosis accompanied by failure of one or more organ systems. This liver disease has a serious prognosis and the four-week mortality rate is 20-30%.